Vaderis Therapeutics Company
Vaderis Therapeutics is a clinical-stage biotechnology company developing targeted therapies for rare vascular diseases. The company focuses on hereditary hemorrhagic telangiectasia (HHT) and other diseases associated with vascular malformations, with the aim of addressing underlying disease mechanisms rather than managing symptoms alone. Its lead investigational therapy, VAD044 (engasertib), is an oral allosteric AKT inhibitor designed to restore vascular balance and reduce the formation and effects of abnormal blood vessels. Vaderis conducts clinical development and research to advance therapies for patients with rare and underserved vascular conditions.
Founded Date:
2019-01-01
Employee Number:
11-50
Headquarters:
Basel, Basel-Stadt, Switzerland, Europe
Industry:
Drug Discovery & Development
Super Industry:
Biopharma & Life Science Tools
Investors:
EQT Life Sciences, Medicxi, Omega Funds, Perceptive Advisors, TCG Crossover
Ipo Status:
private
City:
Basel
Region:
Basel-Stadt
Country:
Switzerland
Founders:
Damien Picard, Nicholas Benedict, Pierre Mezard